

Neutrophils

Subjects: **Immunology**

Contributor: Mirre De Bondt , Niels Hellings , Ghislain Opdenakker , Sofie Struyf

Neutrophils are the most abundant circulating and first-responding innate myeloid cells and have so far been underestimated in the context of multiple sclerosis (MS). MS is the most frequent, immune-mediated, inflammatory disease of the central nervous system. MS is treatable but not curable and its cause(s) and pathogenesis remain elusive. The involvement of neutrophils in MS pathogenesis has been suggested by the use of preclinical animal disease models, as well as on the basis of patient sample analysis. In this review, we provide an overview of the possible mechanisms and functions by which neutrophils may contribute to the development and pathology of MS. Neutrophils display a broad variety of effector functions enabling disease pathogenesis, including (1) the release of inflammatory mediators and enzymes, such as interleukin-1, myeloperoxidase and various proteinases, (2) destruction and phagocytosis of myelin (as debris), (3) release of neutrophil extracellular traps, (4) production of reactive oxygen species, (5) breakdown of the blood–brain barrier and (6) generation and presentation of autoantigens. An important question relates to the issue of whether neutrophils exhibit a predominantly proinflammatory function or are also implicated in the resolution of chronic inflammatory responses in MS.

Autoimmunity

multiple sclerosis

antigen presentation

1. Introduction

Neutrophilic granulocytes are the most abundant cell population (70%) in the circulating leukocyte fraction in the human species. They belong to the polymorphonuclear cell family together with basophils and eosinophils because of their multi-lobular nucleus ^{[1][2]}. After their formation in the bone marrow from a common myeloid progenitor cell, they circulate in the bloodstream for 7–10 h, after which they migrate into tissues and exert their functions. These innate immune cells are often seen as ‘first responder cells’ during acute inflammation. They are highly motile cells and were assumed to display a short lifespan of about one day. The latter survival time is currently disputed because neutrophils could still be detected after 7 days under certain conditions ^{[3][4]}. Such refinement of detection may be limited to specific subpopulations of neutrophils and yields discussions about future immunophenotyping of neutrophil subsets (*vide infra*). Under physiological conditions, the majority of neutrophils are patrolling cells and just circulate through the body in resting state to avoid the release of their toxic, intracellular content.

2. The Role of Neutrophils

Activation of neutrophils requires two steps: (1) priming of neutrophils by bacterial products or cytokines/chemokines and (2) binding of activating signals to membrane receptors at the site of injury ^[5].

In response to an inflammatory stimulus, neutrophils are quickly activated through G-protein-coupled receptors (GPCRs) and migrate along four types of chemical gradients to the site of infection/injury/inflammation, which is called 'chemotaxis'. These four chemotactic cues may be bacterial formyl peptides, complement molecules C3a and C5a, leukotrienes or chemotactic cytokines, dubbed chemokines [6]. The prototype of human neutrophil chemokine is granulocyte chemotactic protein-1, named interleukin-8, and later still renamed CXC chemokine ligand (CXCL)-8 [7]. CXCL8 uses two CXC chemokine receptors (CXCR): CXCR1 and CXCR2 (*vide infra*). Upon arrival at the target sites, neutrophils are activated and execute their effector functions, mainly intended for the elimination of pathogens. By the release of cytokines and chemokines, neutrophils amplify the inflammatory cascade and attract other immune cells. Neutrophils can act as phagocytes and internalize microorganisms or particles, foremost when these are coated with opsonins, such as antibodies or complement molecules. To kill the engulfed pathogens, reactive oxygen species (ROS) are produced and released into the phagosome. Neutrophils also secrete granules which are classified in one system (on the basis of biosynthesis during the maturation of neutrophils in the bone marrow) in the following three categories: primary or azurophilic granules (containing, for instance, myeloperoxidase (MPO) and the serine proteinases neutrophil elastase (NE), cathepsin G and proteinase 3), secondary or specific granules (containing, e.g., lysozyme, lactoferrin and neutrophil gelatinase-associated lipocalin) and tertiary or gelatinase B granules. In addition to granules, neutrophils also contain smaller secretory vesicles with alkaline phosphatase, cytokines/chemokines and CD35, the latter of which is first released upon activation [8]. The release of this antimicrobial content is called degranulation, in which the order is reciprocal with the synthesis in the bone marrow, namely secretory vesicles and tertiary granules released first and primary granules last. A recently discovered function of neutrophils is the formation of neutrophil extracellular traps (NETs), which includes the release of fiber-like structures of DNA [9]. These NETs trap and eliminate microbes independently of phagocytosis and may also serve as a physical barrier to prevent spreading of pathogens. Neutrophils also act as immunomodulators by promoting the maturation of professional antigen presenting cells (APCs) [10]. Coculturing of neutrophils and dendritic cells (DCs) leads to activation of DCs. Activation is dependent on cell-to-cell contact and is accompanied by an upregulated expression of CD40, CD86 and human leukocyte antigen-DR isotype (HLA-DR) [11]. Another recent proposal is that neutrophils themselves act as alternative APCs and in this way participate in adaptive immunity [12][13]. It is believed that neutrophils influence adaptive immunity through the transport of antigens to lymph nodes (LNs), presentation of antigens to T cells and interaction with APCs. This function implies that such neutrophils may leave the site of antigen capture, enter the lymph circulation and transport and present antigens, together being processes in need of cumulated time intervals which presumably supersede the supposed life-span of only one day [14]. Bone marrow-derived murine neutrophils are able to transform into a DC-like population after treatment with granulocyte-macrophage colony-stimulating factor (GM-CSF), called 'neutrophil-DC hybrids' (Figure 1). These DC-neutrophil hybrid cells express markers of both neutrophils (Ly6G, CXCR2) and DCs (major histocompatibility complex class II (MHC II), CD80/86) and develop some APC-like properties. They thus acquire DC characteristics while maintaining intrinsic neutrophil features such as phagocytosis and NET release [15][16]. Regarding the origin of the hybrid population, Geng et al. showed that they originate from immature band cells that either progress into mature polymorphonuclear cells or transdifferentiate into neutrophil–DC hybrids. These authors also demonstrate that the hybrid population is able to present bacterial antigens to CD4⁺ T cells and assist in rapid bacterial clearance in vivo [15][16]. Also, in mouse

models for inflammatory diseases, MHC II and CD86 expressing neutrophils, that are able to present antigens to naive CD4⁺ T cells, were isolated [17]. These neutrophil-DC hybrids originate from transdifferentiated neutrophils after extravasation at inflammatory sites. So, both immature and mature murine neutrophils are able to form hybrids *in vitro*, as well as *in vivo*. Regarding the required stimulus to acquire antigen presenting capacities of murine neutrophils, Radsak et al. reported the expression of MHC II and costimulatory molecules after coculturing of neutrophils with T cells and antigens [18]. Furthermore, Abi Abdallah et al. stressed the need for cell-cell-dependent contact between T cells and neutrophils, as separation by a transwell system abrogated the T cell-induced expression of MHC II on neutrophils [19]. These neutrophils are able to process and present antigens to CD4⁺ T cells, induce their proliferation and stimulate differentiation of T helper (Th) 1 and Th17 cells *in vitro*.




Figure 1. Comparison of the functions and phenotype of neutrophils, dendritic cells (DCs) and the neutrophil-DC hybrids. The hybrid population is characterized by combined functions of both DCs (antigen presentation and T cell activation) and neutrophils (phagocytic clearance of pathogens, etc.). The expression profile of hybrid cells is defined as a mixed phenotype with expression of markers from both neutrophils and DCs [10][11]. They morphologically resemble DCs, whereas their nucleus was detected as both an oval shape or as multi-lobular [20]. Hu = human, Mo = mouse.

Resting human neutrophils under physiological conditions do not express markers typically found on APCs and are not able to induce proliferation of naive T cells. However, human peripheral blood neutrophils start to express DC markers (e.g., MHC II, CD80, CD83, CD86 and CC chemokine receptor 6) after *in vitro* activation by GM-CSF, interferon (IFN)- γ and interleukin (IL)-3. This generates neutrophil-DC hybrids with characteristics of APCs while maintaining typical features of neutrophils. It was shown that mature as well as immature human neutrophils are able to transdifferentiate into hybrids [13][21][22][23]. These APC-like neutrophils are not only an *in vitro* phenomenon, as they are also detected in patient samples (e.g., synovial fluid from patients with rheumatoid arthritis and blood

from patients with Wegener's granulomatosis), where the expression of MHC II, CD80, CD83 and CD86 on neutrophils is upregulated [13][23][24][25]. Vono et al. used freshly isolated human neutrophils to show their ability of presenting antigens in vivo to antigen-specific CD4⁺ T cells [14]. They found that the supernatant from antigen-specific, activated T cells induces the expression of MHC II and costimulatory molecules on neutrophils, which are then able to present antigens via interaction with T cells. Radsak et al. demonstrated that unstimulated human neutrophils are able to cause proliferation of antigen-specific T cells after co-culturing with T cells and their antigens [18]. This ability is dependent on MHC II, as blocking MHC II on neutrophils inhibits their antigen presenting capacity.

Lok et al. investigated the presence of neutrophils in LNs under physiological conditions [4]. Using flow cytometry and intravital imaging analysis, they were able to detect the presence of both human and murine neutrophils in LNs under homeostatic, unstimulated conditions. These cells enter the LNs via high endothelial venules and then circulate through the lymphatics. LN-neutrophils show a phenotype distinct from neutrophils derived from the peripheral blood. More specifically, LN-neutrophils display higher expression of CXCR4, MHC II and costimulatory molecules. They carry immunoglobulin G (IgG)-opsonized cargo, such as immune complexes, and are mostly found within the interfollicular region of the LNs, which is the area where CD4⁺ T cells are located for their antigen searches. Also, with the use of confocal microscopy, interactions are revealed between neutrophils and DCs in the LN cortex. Finally, when stimulated ex vivo with immune complexes, neutrophils upregulate MHC II and are able to activate CD4⁺ T cells. Altogether, this makes neutrophils ideal candidates to execute homeostatic immune surveillance, as well as to reactivate (autoreactive) T cells, by delivering circulating antigens (such as immune complexes or autoantigens) to the LN, where they can stimulate the adaptive immune cells.

References

1. Opdenakker, G.; Fibbe, W.E.; Van Damme, J. The Molecular Basis of Leukocytosis. *Immunol. Today* 1998, 19, 182–189.
2. Kolackowska, E.; Kubes, P. Neutrophil Recruitment and Function in Health and Inflammation. *Nat. Rev. Immunol.* 2013, 13, 159–175.
3. Lahoz-Beneytez, J.; Elemans, M.; Zhang, Y.; Ahmed, R.; Salam, A.; Block, M.; Niederaalt, C.; Asquith, B.; Macallan, D. Human Neutrophil Kinetics: Modeling of Stable Isotope Labeling Data Supports Short Blood Neutrophil Half-Lives. *Blood* 2016, 127, 3431–3438.
4. Lok, L.S.C.; Dennison, T.W.; Mahbubani, K.M.; Saeb-Parsy, K.; Chilvers, E.R.; Clatworthy, M.R. Phenotypically Distinct Neutrophils Patrol Uninfected Human and Mouse Lymph Nodes. *Proc. Natl. Acad. Sci. USA* 2019, 116, 19083–19089.
5. Miralda, I.; Uriarte, S.M.; McLeish, K.R. Multiple Phenotypic Changes Define Neutrophil Priming. *Front. Cell. Infect. Microbiol.* 2017, 7, 217.

6. Metzemaekers, M.; Gouwy, M.; Proost, P. Neutrophil Chemoattractant Receptors in Health and Disease: Double-Edged Swords. *Cell. Mol. Immunol.* 2020, 17, 433–450.
7. Van Damme, J.; Van Beeumen, J.; Opdenakker, G.; Billiau, A. A Novel, NH₂-Terminal Sequence-Characterized Human Monokine Possessing Neutrophil Chemotactic, Skin-Reactive, and Granulocytosis-Promoting Activity. *J. Exp. Med.* 1988, 167, 1364–1376.
8. Cowland, J.B.; Borregaard, N. The Individual Regulation of Granule Protein mRNA Levels during Neutrophil Maturation Explains the Heterogeneity of Neutrophil Granules. *J. Leukoc. Biol.* 1999, 66, 989–995.
9. Brinkmann, V.; Reichard, U.; Goosmann, C.; Fauler, B.; Uhlemann, Y.; Weiss, D.S.; Weinrauch, Y.; Zychlinsky, A. Neutrophil Extracellular Traps Kill Bacteria. *Science* 2004, 303, 1532–1535.
10. Steinbach, K.; Piedavent, M.; Bauer, S.; Neumann, J.T.; Friese, M.A. Neutrophils Amplify Autoimmune Central Nervous System Infiltrates by Maturing Local APCs. *J. Immunol.* 2013, 191, 4531–4539.
11. Megjiovanni, A.M.; Sanchez, F.; Robledo-Sarmiento, M.; Morel, C.; Gluckman, J.C.; Boudaly, S. Polymorphonuclear Neutrophils Deliver Activation Signals and Antigenic Molecules to Dendritic Cells: A New Link between Leukocytes Upstream of T Lymphocytes. *J. Leukoc. Biol.* 2006, 79, 977–988.
12. Takashima, A.; Yao, Y. Neutrophil Plasticity: Acquisition of Phenotype and Functionality of Antigen-Presenting Cell. *J. Leukoc. Biol.* 2015, 98, 489–496.
13. Reinisch, W.; Tillinger, W.; Lichtenberger, C.; Gangl, A.; Willheim, M.; Scheiner, O.; Steger, G. In Vivo Induction of HLA-DR on Human Neutrophils in Patients Treated with Interferon-Gamma. *Blood* 1996, 87, 3068.
14. Vono, M.; Lin, A.; Norrby-Teglund, A.; Koup, R.A.; Liang, F.; Loré, K. Neutrophils Acquire the Capacity for Antigen Presentation to Memory CD4(+) T Cells in Vitro and Ex Vivo. *Blood* 2017, 129, 1991–2001.
15. Matsushima, H.; Geng, S.; Lu, R.; Okamoto, T.; Yao, Y.; Mayuzumi, N.; Kotol, P.F.; Chojnacki, B.J.; Miyazaki, T.; Gallo, R.L.; et al. Neutrophil Differentiation into a Unique Hybrid Population Exhibiting Dual Phenotype and Functionality of Neutrophils and Dendritic Cells. *Blood* 2013, 121, 1677–1689.
16. Geng, S.; Matsushima, H.; Okamoto, T.; Yao, Y.; Lu, R.; Page, K.; Blumenthal, R.M.; Ward, N.L.; Miyazaki, T.; Takashima, A. Emergence, Origin, and Function of Neutrophil-Dendritic Cell Hybrids in Experimentally Induced Inflammatory Lesions in Mice. *Blood* 2013, 121, 1690–1700.
17. Ostanin, D.V.; Kurmaeva, E.; Furr, K.; Bao, R.; Hoffman, J.; Berney, S.; Grisham, M.B. Acquisition of Antigen-Presenting Functions by Neutrophils Isolated from Mice with Chronic Colitis. *J. Immunol.* 2012, 188, 1491–1502.

18. Radsak, M.; Iking-Konert, C.; Stegmaier, S.; Andrassy, K.; Hänsch, G.M. Polymorphonuclear Neutrophils as Accessory Cells for T-Cell Activation: Major Histocompatibility Complex Class II Restricted Antigen-Dependent Induction of T-Cell Proliferation. *Immunology* 2000, 101, 521–530.
19. Abi Abdallah, D.S.; Egan, C.E.; Butcher, B.A.; Denkers, E.Y. Mouse Neutrophils Are Professional Antigen-Presenting Cells Programmed to Instruct Th1 and Th17 T-Cell Differentiation. *Int. Immunol.* 2011, 23, 317–326.
20. Fites, J.S.; Gui, M.; Kernien, J.F.; Negoro, P.; Dagher, Z.; Sykes, D.B.; Nett, J.E.; Mansour, M.K.; Klein, B.S. An Unappreciated Role for Neutrophil-DC Hybrids in Immunity to Invasive Fungal Infections. *PLoS Pathog.* 2018, 14.
21. Gosselin, E.J.; Wardwell, K.; Rigby, W.F.; Guyre, P.M. Induction of MHC Class II on Human Polymorphonuclear Neutrophils by Granulocyte/Macrophage Colony-Stimulating Factor, IFN-Gamma, and IL-3. *J. Immunol.* 1993, 151, 1482–1490.
22. Iking-Konert, C.; Ostendorf, B.; Sander, O.; Jost, M.; Wagner, C.; Joosten, L.; Schneider, M.; Hansch, G.M. Transdifferentiation of Polymorphonuclear Neutrophils to Dendritic-like Cells at the Site of Inflammation in Rheumatoid Arthritis: Evidence for Activation by T Cells. *Ann. Rheum. Dis.* 2005, 64, 1436–1442.
23. Lin, A.; Loré, K. Granulocytes: New Members of the Antigen-Presenting Cell Family. *Front. Immunol.* 2017, 8, 1781.
24. Mudzinski, S.P.; Christian, T.P.; Guo, T.L.; Cirenza, E.; Hazlett, K.R.; Gosselin, E.J. Expression of HLA-DR (Major Histocompatibility Complex Class II) on Neutrophils from Patients Treated with Granulocyte-Macrophage Colony-Stimulating Factor for Mobilization of Stem Cells. *Blood.* 1995, 86, 2452–2453.
25. Spagnoli, G.C.; Juretic, A.; Rosso, R.; Van Bree, J.; Harder, F.; Heberer, M. Expression of HLA-DR in Granulocytes of Polytraumatized Patients Treated with Recombinant Human Granulocyte Macrophage—Colony-Stimulating Factor. *Hum. Immunol.* 1995, 43, 45–50.

Retrieved from <https://encyclopedia.pub/entry/history/show/131296>